Ratings Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 14/07/2025 BST			5-day change	1st Jan Change
160.13 ^USD	-1.64%		-1.43%	-18.51%

07-09	Evercore ISI Adjusts Price Target on IQVIA to $180 From $170, Maintains Outperform Rating	MT
07-08	Leerink Partners Adjusts Price Target on IQVIA Holdings to $200 From $210, Maintains Outperform Rating	MT

Highlights: Iqvia Holdings Inc.

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: Iqvia Holdings Inc.

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings Chart: Iqvia Holdings Inc.

Source: Surperformance

ESG chart: Iqvia Holdings Inc.

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	IQVIA HOLDINGS INC.				28.16B
	LONZA GROUP AG				50.02B
	BEONE MEDICINES LTD.				29.65B
	CELLTRION, INC.				28.69B
	EUROFINS SCIENTIFIC SE				12.7B
	ICON PUBLIC LIMITED COMPANY				11.96B
	QIAGEN N.V.				10.42B
	MEDPACE HOLDINGS, INC.				9.3B
	Average				22.61B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes